BTEE:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (USD)

ETF | Others |

Last Closing

USD 7.0655

Change

-0.12 (-1.62)%

Market Cap

N/A

Volume

9.33K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-20 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-1.25 (-0.66%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-1.19 (-1.01%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 547.46B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.01 (+0.04%)

USD 547.46B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+0.25 (+0.35%)

USD 266.08B
0QZO:LSE 0QZO

-1.55 (-1.64%)

USD 258.54B
0QZ3:LSE Qualcomm Inc.

-1.56 (-0.91%)

USD 202.26B
PRJU:LSE Amundi Index Solutions - Amund..

-0.04 (-0.12%)

USD 200.01B
0R24:LSE Intel Corp.

-0.80 (-3.74%)

USD 196.14B

ETFs Containing BTEE:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.69% 70% C- 67% D+
Dividend Return 0.27% 38% F 66% D+
Total Return 10.97% 70% C- 67% D+
Trailing 12 Months  
Capital Gain 23.02% 79% B- 75% C
Dividend Return 0.30% 38% F 66% D+
Total Return 23.32% 78% C+ 74% C
Trailing 5 Years  
Capital Gain 50.35% 69% C- 74% C
Dividend Return 0.99% 28% F 29% F
Total Return 51.34% 69% C- 73% C
Average Annual (5 Year Horizon)  
Capital Gain 5.06% 51% F 57% F
Dividend Return 5.18% 50% F 56% F
Total Return 0.13% 13% F 36% F
Risk Return Profile  
Volatility (Standard Deviation) 18.71% 37% F 53% F
Risk Adjusted Return 27.71% 44% F 58% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.